An individual drug discovery program focused on lead optimization of 4E-BP1 mimetic compounds that regulate eIF4E/eIF4G using free-energy perturbation (FEP), with the aim of generating a clinical candidate within 1–2 years and subsequently entering into an out-licensing agreement.